Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Thermo Fisher, Cynvenio Partner as Liquid Biopsy Technology Expands
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Thermo Fisher Scientific (Carlsbad, Calif.) and Cynvenio Biosystems (Westlake Village, Calif.) have signed a distribution agreement for the LiquidBiopsy platform. The combination of Cynvenio’s...
Medicare Announces Timeline for Shifting from Volume to Value Based Reimbursement
By Kelly A. Briganti, JD, Editorial Director G2 Intelligence There has been much discussion about moving away from fee for service reimbursement and the need to tie reimbursement to the value provided, rather than the amount of care provided. That discussion takes...
The New 59 X(EPSU) Modifiers, X’d For Now
By Christopher P. Young, Editor, G2 Compliance Advisor The latest communication from the Centers for Medicare and Medicaid Services (CMS) concerning new modifiers, referred to as X(EPSU), intended to replace the 59 modifier, says that while the new modifiers are...
FDA Authorizes Marketing of 23andMe Direct-to-Consumer Genetic Screening Test
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence Only a little more than a year after receiving an FDA warning letter telling 23andMe to stop marketing its direct-to-consumer Personal Genome Service, the company finally has a bit of good news. The FDA...
Patient Test Requests Not Driving Health Care Costs
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Physicians' perceptions of the "demanding patient" may not be based in reality. According to a new study, published online Feb. 12 in JAMA Oncology, patients make demands for additional cancer...
LifeCode Obtains CAP Laboratory Accreditation Raises $20.5 Million
By Ron Shinkman, Editor, Laboratory Industry Report LifeCode, the California-based laboratory firm that focuses on next-generation sequencing assays, has obtained laboratory accreditation from the College of American Pathologists and raised $20.5 million from a...
Claritas Genomics Raises $15 Million to Expand Operations, Test Menu
By Stephanie Murg, Managing Director, G2 Intelligence Genetic diagnostic testing company Claritas Genomics (Cambridge, Mass.) has secured $15 million to fund expansion of its commercial operations and launch novel next generation sequencing-based tests for...
Human Longevity Licenses Assays, Platform from Personal Genome Diagnostics
By Ron Shinkman, Editor, Laboratory Industry Report Human Longevity, Inc., a California-based genomic laboratory, has entered into an agreement with Personal Genomic Diagnostics, Inc. to license the latter's products to expand its ability to analyze cancer genomes....
HHS Secretary Calls for Bi-Partisan Efforts to Improve Health Care
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence Health and Human Services Secretary Sylvia Matthews Burwell recently delivered a speech to the New America Foundation calling for Congress and the Administration to work together to capitalize on...
Medicare Fee-For-Service is Top of List for Fraud, Waste and Abuse
By Christopher P. Young, Editor, G2 Compliance Advisor Medicare fee-for-service (FFS) tops a list of 13 high error rate government programs estimated to have lost $106 billion during fiscal year 2013 to improper payments. According to the authors of a study by...